LeMaitre Vascular, Inc. (NASDAQ:LMAT) Expected to Post Quarterly Sales of $39.99 Million

Brokerages expect LeMaitre Vascular, Inc. (NASDAQ:LMAT) to post $39.99 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for LeMaitre Vascular’s earnings. The highest sales estimate is $40.10 million and the lowest is $39.63 million. LeMaitre Vascular reported sales of $37.55 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.5%. The company is expected to report its next earnings results on Thursday, February 24th.

According to Zacks, analysts expect that LeMaitre Vascular will report full-year sales of $154.89 million for the current fiscal year, with estimates ranging from $154.55 million to $155.02 million. For the next financial year, analysts forecast that the firm will post sales of $167.35 million, with estimates ranging from $164.20 million to $170.80 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, October 28th. The medical instruments supplier reported $0.30 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.33 by ($0.03). LeMaitre Vascular had a return on equity of 14.15% and a net margin of 18.21%. The business had revenue of $38.37 million during the quarter, compared to analyst estimates of $39.05 million. During the same quarter last year, the firm posted $0.37 EPS. The company’s quarterly revenue was up 5.4% compared to the same quarter last year.

Several equities analysts have weighed in on LMAT shares. Roth Capital lifted their price objective on shares of LeMaitre Vascular from $55.00 to $58.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 3rd. Zacks Investment Research cut shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research report on Tuesday, November 2nd. Jefferies Financial Group started coverage on shares of LeMaitre Vascular in a research report on Thursday, September 16th. They set a “buy” rating and a $70.00 price objective on the stock. Finally, Barrington Research lifted their price objective on shares of LeMaitre Vascular from $59.00 to $64.00 and gave the stock an “outperform” rating in a research report on Friday, July 30th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $63.80.

NASDAQ LMAT traded up $0.86 on Thursday, hitting $50.88. 58,003 shares of the stock were exchanged, compared to its average volume of 124,655. LeMaitre Vascular has a 52-week low of $34.23 and a 52-week high of $64.50. The company has a market cap of $1.11 billion, a P/E ratio of 38.55, a price-to-earnings-growth ratio of 4.03 and a beta of 1.30. The business’s 50-day moving average price is $54.40.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 2nd. Stockholders of record on Friday, November 19th will be issued a dividend of $0.11 per share. This represents a $0.44 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Thursday, November 18th. LeMaitre Vascular’s dividend payout ratio is currently 33.33%.

In other news, Director David B. Roberts sold 19,712 shares of the business’s stock in a transaction on Wednesday, November 3rd. The shares were sold at an average price of $52.24, for a total transaction of $1,029,754.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 14.10% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in LMAT. Amundi acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at $14,065,000. ProShare Advisors LLC lifted its stake in shares of LeMaitre Vascular by 3,672.6% in the 2nd quarter. ProShare Advisors LLC now owns 186,254 shares of the medical instruments supplier’s stock valued at $11,365,000 after purchasing an additional 181,317 shares during the last quarter. BlackRock Inc. lifted its stake in shares of LeMaitre Vascular by 5.9% in the 3rd quarter. BlackRock Inc. now owns 3,115,834 shares of the medical instruments supplier’s stock valued at $165,420,000 after purchasing an additional 173,671 shares during the last quarter. Morgan Stanley lifted its stake in shares of LeMaitre Vascular by 61.3% in the 1st quarter. Morgan Stanley now owns 302,995 shares of the medical instruments supplier’s stock valued at $14,781,000 after purchasing an additional 115,111 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in LeMaitre Vascular by 109.8% during the 2nd quarter. Goldman Sachs Group Inc. now owns 211,290 shares of the medical instruments supplier’s stock worth $12,893,000 after acquiring an additional 110,593 shares during the last quarter. 81.39% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy.

Recommended Story: Buy Rating

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.